Longidaza suppositories (supp.vag/rect. 3000ME No. 10) - buy in Moscow, price in pharmacies from 1,759 rubles, instructions for use, reviews

Nosological classification (ICD-10)

A16.9 Respiratory tuberculosis of unspecified localization without mention of bacteriological or histological confirmation
J63.4 Siderosis
J84.1 Other interstitial lung diseases with mention of fibrosis
J84.8 Other specified interstitial pulmonary diseases
L94.0 Localized scleroderma [morphea]
N13.5 Kink and stricture of the ureter without hydronephrosis
N30.1 Interstitial cystitis (chronic)
N35 Urethral stricture
N40 Prostatic hyperplasia
N41.1 Chronic prostatitis
N48.8 Other specified diseases of the penis
N71 Inflammatory diseases of the uterus, except the cervix
N85.6 Intrauterine synechiae
N97.1 Female infertility of tubal origin
N99.1 Postoperative urethral stricture
N99.4 Postoperative adhesions in the pelvis
T14.1 Open wound of unspecified body area
Z100* CLASS XXII Surgical practice

Indications and contraindications for taking Longidaza

This drug is prescribed not only for the treatment, but also for the prevention of many diseases with connective tissue hyperplasia syndrome. It is used in the following medical fields:

Gynecology: for inflammatory diseases of the genital organs, as well as for adhesions in the pelvic area.
Pulmonology: fibrosing and sclerosing diseases of the lungs and respiratory tract, tuberculosis.
Urology: chronic prostatitis and complicated cystitis.
Surgery: prevention of adhesions after extensive abdominal surgery.
Dermatovenereology: scleroderma, rough, keloid, disfiguring scars after various skin pathological processes.

There are also contraindications to the use of Longidase and, despite the low toxicity of the drug, there are quite a few of them:

Individual intolerance to hyaluronidase.
Oncological diseases.
CKD.
Bleeding and hemorrhage.
Age under 18 years.
Infections during the acute period of the disease.

Pharmacodynamics

Longidase® has hyaluronidase (enzymatic proteolytic) activity of prolonged action, chelating, antioxidant, immunomodulatory and moderate anti-inflammatory properties.

Prolongation of the action of the enzyme is achieved by covalent binding of it to a physiologically active high-molecular carrier (activated derivative of poly-1,4-ethylenepiperazine N-oxide, an analogue of the drug Polyoxidonium®), which has its own pharmacological activity. Longidase® exhibits antifibrotic properties, weakens the course of the acute phase of inflammation, regulates (increases or decreases depending on the initial level) the synthesis of inflammatory mediators (IL-1 and tumor necrosis factor-alpha), increases the humoral immune response and the body's resistance to infection.

The pronounced antifibrotic properties of Longidase® are ensured by the conjugation of hyaluronidase with a carrier, which significantly increases the resistance of the enzyme to denaturing influences and the action of inhibitors: the enzymatic activity of Longidase® is maintained when heated to 37 °C for 20 days, while native hyaluronidase loses under the same conditions your activity during the day. The Longidaza® preparation ensures the simultaneous local presence of the proteolytic enzyme hyaluronidase and a carrier capable of binding matrix components released during hydrolysis, enzyme inhibitors and stimulators of collagen synthesis (including iron, copper ions, heparin). Thanks to these properties, Longidaza® has not only the ability to depolymerize the connective tissue matrix in fibrogranulomatous formations, but also suppress the reverse regulatory reaction aimed at the synthesis of connective tissue components.

The specific substrate of testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix. As a result of depolymerization (breaking the bond between C1 acetylglucosamine and C4 glucuronic or induronic acids), glycosaminoglycans change their basic properties: viscosity decreases, the ability to bind water and metal ions decreases, the permeability of tissue barriers temporarily increases, fluid movement in the intercellular space is facilitated, and the elasticity of connective tissue increases. , which manifests itself in a decrease in tissue swelling, flattening of scars, an increase in the range of motion of joints, a decrease in contractures and prevention of their formation, and a decrease in adhesions.

Biochemical, immunological, histological and electron microscopic studies have proven that Longidaza® does not damage normal connective tissue, but causes destruction of connective tissue altered in composition and structure in the area of fibrosis.

Longidaza® does not have mutagenic, embryotoxic, teratogenic or carcinogenic effects.

The drug was well tolerated by patients; no local or general allergic reactions were noted.

The use of Longidase® in therapeutic doses during or after surgical treatment does not cause worsening of the postoperative period or progression of the infectious process; does not slow down bone tissue recovery.

Longidaza (supp.vag/rect. 3000IU No. 10)

A country

Russia
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.

Active substance

Hyaluronidase + Azoximer bromide Read more on the official website of the drug: Longidaza® - https://www.longidaza.ru/

Compound

Dosage form: vaginal and rectal suppositories Composition per suppository: Active substance: Bovhyaluronidase azoximer (Longidase®) – 3000 IU Excipient: cocoa butter – to obtain a suppository weighing 1.3 g Description: torpedo-shaped suppositories, light yellow in color with a weak specific the smell of cocoa butter, marbling of coloring is allowed. Release form: 5 suppositories in a blister pack made of polyvinyl chloride film. Two blister packs in a cardboard box along with instructions for use.

pharmachologic effect

PHARMACODYNAMICS Longidase® has hyaluronidase (enzymatic) activity of prolonged action, chelating, antioxidant, immunomodulatory and moderately expressed anti-inflammatory properties. Prolongation of the action of the enzyme is achieved by covalent binding of the enzyme to a physiologically active polymer carrier (azoximer). Longidase® exhibits antifibrotic properties, weakens the course of the acute phase of inflammation, regulates (increases or decreases depending on the initial level) the synthesis of inflammatory mediators (interleukin-1 and tumor necrosis factor - alpha), increases the humoral immune response and the body's resistance to infection. Pronounced antifibrotic the properties of Longidase are ensured by the conjugation of hyaluronidase with a carrier, which significantly increases the resistance of the enzyme to denaturing influences and the action of inhibitors: the enzymatic activity of Longidase is maintained when heated to 37 ° C for 20 days, while native hyaluronidase under the same conditions loses its activity within days. The Longidaza® preparation ensures the simultaneous local presence of the enzyme hyaluronidase and a carrier capable of binding enzyme inhibitors and stimulators of collagen synthesis (iron, copper ions, heparin, etc.) released during hydrolysis of matrix components. Thanks to these properties, Longidase® has not only the ability to depolymerize the connective tissue matrix in fibrogranulomatous formations, but also suppress the reverse regulatory reaction aimed at the synthesis of connective tissue components. The specific substrate of testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate , chondroitin-6-sulfate), which form the basis of the connective tissue matrix. As a result of depolymerization (breaking the bond between C1 acetylglucosamine and C4 glucuronic or induronic acids), glycosaminoglycans change their basic properties: viscosity decreases, the ability to bind water and metal ions decreases, the permeability of tissue barriers temporarily increases, fluid movement in the intercellular space is facilitated, and the elasticity of connective tissue increases. , which manifests itself in a decrease in tissue swelling, flattening of scars, an increase in the range of motion of joints, a decrease in contractures and prevention of their formation, and a decrease in adhesions. Biochemical, immunological, histological and electron microscopic studies have proven that Longidaza® does not damage normal connective tissue, but causes destruction of connective tissue that has changed in composition and structure in the area of fibrosis. Longidaza® does not have a mutagenic, embryotoxic, teratogenic or carcinogenic effect. The drug is good tolerated by patients, no local or general allergic reactions were noted. The use of Longidase in therapeutic doses during or after surgical treatment does not cause worsening of the postoperative period or progression of the infectious process; does not slow down bone tissue recovery. PHARMACOKINETICS An experimental study of pharmacokinetics made it possible to establish that when administered rectally, Longidaza® is characterized by a high rate of distribution in the body, is well absorbed into the systemic circulation and reaches a maximum concentration in the blood after 1 hour. The half-life of distribution is about 0.5 hours, the half-life of elimination is from 42 to 84 hours. It is excreted primarily by the kidneys. The drug penetrates all organs and tissues, including passing through the blood-brain and blood-ophthalmic barriers. The absence of tissue cumulation was established. The bioavailability of Longidaza® after rectal administration is high: about 90%.

Indications for use

Adults and adolescents over 12 years of age as monotherapy and as part of complex therapy for diseases accompanied by connective tissue hyperplasia, including against the background of an inflammatory process: - in urology: chronic prostatitis, interstitial cystitis, urethral and ureteral strictures, Peyronie's disease, initial stage benign prostatic hyperplasia, prevention of scar formation and strictures after surgical interventions on the urethra, bladder, ureters; — in gynecology: adhesions (prevention and treatment) in the pelvis in chronic inflammatory diseases of the internal genital organs, after gynecological manipulations, including induced abortions, previous surgical interventions on the pelvic organs; intrauterine synechiae, tubo-peritoneal infertility, chronic endomyometritis; — in dermatovenerology: limited scleroderma, prevention of fibrotic complications of sexually transmitted infections; — in surgery: prevention and treatment of adhesions after surgical interventions on the abdominal organs; long-term non-healing wounds; — in pulmonology and phthisiology: pneumofibrosis, siderosis, tuberculosis (cavernous fibrous, infiltrative, tuberculoma), interstitial pneumonia, fibrosing alveolitis, pleurisy; — to increase the bioavailability of antibacterial therapy in urology, gynecology, dermatovenerology, surgery, pulmonology, etc.

Mode of application

Longidaza® suppositories 3000 IU are recommended for rectal or vaginal use once a day at night for a course of 10 to 20 administrations. For adolescents from 12 to 18 years old, suppositories are administered only rectally. Adults and adolescents over 12 years of age rectally: 1 suppository 1 time per day after cleansing the intestines. Adults vaginally: 1 suppository 1 time per day (at night), the suppository is inserted into the vagina in a lying position. The administration regimen is adjusted depending on the severity, stage and duration of the disease: Longidaza® is prescribed every other day or at intervals of 2-3 days. Recommended regimens and doses: - in urology: 1 suppository every other day for 10 injections, then after 2-3 days 10 injections, a total course of 20 suppositories. — in gynecology: rectally or vaginally, 1 suppository every 2 days, 10 injections, then, if necessary, maintenance therapy is prescribed. — in dermatovenerology: 1 suppository every 1-2 days, 10-15 injections. — in surgery: 1 suppository every 2-3 days, 10 injections. — in pulmonology and phthisiology: 1 suppository every 2-4 days, 10-20 injections. If necessary, a repeat course of Longidaza® is recommended no earlier than three months later or long-term maintenance therapy of 1 suppository once every 5-7 days for 3-4 months.

Interaction

Longidaza® can be combined with antibiotics, antiviral, antifungal drugs, and bronchodilators. When prescribed in combination with other drugs (antibiotics, local anesthetics, diuretics), the possibility of increasing bioavailability and enhancing their action should be taken into account. When used together with large doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogens or antihistamines, the enzymatic activity of Longidase® may be reduced. Longidaza® should not be used simultaneously with drugs containing furosemide, benzodiazepines, or phenytoin.

Side effect

The frequency of adverse reactions is presented according to the following classification: very common > 10%; frequent > 1% and 0.1% and 0.01% and Contraindications - hypersensitivity to drugs based on hyaluronidase; - pulmonary hemorrhage and hemoptysis; - fresh hemorrhage into the vitreous body; — malignant neoplasms; - acute renal failure; - children under 12 years of age (no clinical trial results); - pregnancy and breastfeeding. WITH CAUTION Use with caution no more than once a week in patients with chronic renal failure or a history of pulmonary hemorrhage. USE DURING PREGNANCY AND BREASTFEEDING Use during pregnancy and breastfeeding is contraindicated (there is no clinical experience of use).

Overdose

Symptoms of overdose may include chills, fever, dizziness, and hypotension. Administration of the drug is stopped and symptomatic therapy is prescribed.

special instructions

When taking the drug, strictly follow the instructions given in the instructions. If you have any questions, ask your doctor or pharmacist for clarification. If an allergic reaction develops, interrupt the use of Longidaza®. When used against the background of exacerbation of foci of infection, to prevent the spread of infection, it is necessary to prescribe under the guise of antimicrobial agents. If adverse reactions occur, as well as if an adverse reaction occurs that is not mentioned in the instructions for medical use, you should contact your doctor. Do not use the drug if there are visual signs of its unsuitability (defective packaging, change in color of the suppository). If you miss the next dose of the drug, continue to use it as usual (do not administer a double dose). If it is necessary to stop taking Longidaza®, discontinuation can be done immediately, without gradually reducing the dose. INFLUENCE ON THE ABILITY TO DRIVE VEHICLES, MECHANISMS The use of the drug Longidaza® does not affect the ability to drive vehicles, maintain machinery and other types of work that require increased concentration and speed of psychomotor reactions. STORAGE CONDITIONS: In a dry place, protected from light, at a temperature of 2 to 15 °C. Keep away from children.

Pharmacokinetics

An experimental study of the pharmacokinetics of suppositories with an enzyme carrier labeled with tritium made it possible to establish that when administered rectally, the drug is characterized by a high rate of distribution in the body, is well absorbed into the systemic circulation and reaches Cmax in the blood after 1 hour. The half-life of distribution is about 0.5 hours, period elimination half-life is from 42 to 84 hours. It is excreted mainly by the kidneys.

The drug penetrates into all organs and tissues, incl. passes through the BBB and the blood-ophthalmic barrier. The absence of tissue cumulation was established.

The bioavailability of Longidase® rectal suppositories is at least 70%.

Indications for Longidaza®

Adults and children over 12 years of age in the form of monotherapy and as part of complex therapy for diseases accompanied by connective tissue hyperplasia, incl. and against the background of the inflammatory process:

in urology: chronic prostatitis, interstitial cystitis, strictures of the urethra and ureters, Peyronie's disease, the initial stage of benign prostatic hyperplasia, prevention of scar formation and strictures after surgical interventions on the urethra, bladder, ureters;

in gynecology: adhesions (prevention and treatment) in the pelvis in chronic inflammatory diseases of the internal genital organs after gynecological manipulations, incl. induced abortions, previous surgical interventions on the pelvic organs: intrauterine synechiae, tubo-peritoneal infertility, chronic endomyometritis;

in dermatovenerology: limited scleroderma, prevention of fibrotic complications of sexually transmitted infections;

in surgery: prevention and treatment of adhesions after surgical interventions on the abdominal organs, long-term non-healing wounds;

in pulmonology and phthisiology: pneumofibrosis, siderosis, tuberculosis (cavernous fibrous, infiltrative, tuberculoma), interstitial pneumonia, fibrosing alveolitis, pleurisy;

to increase the bioavailability of antibacterial therapy in urology, gynecology, dermatovenereology, surgery, pulmonology.

LONGIDAZE lyophilized powder for the preparation of solution for infusion 3000me No. 5

Longidaza is applied subcutaneously (near the site of the lesion or under scar tissue) or intramuscularly at a dose of 3000 IU in a course of 5 to 25 injections (depending on the disease) with an interval between injections of 3 to 10 days. Methods of application are selected by the doctor depending on the diagnosis, severity of the disease, clinical course, and age of the patient. If necessary, a repeat course is recommended after 2-3 months. In the case of treatment of diseases accompanied by a severe chronic productive process in the connective tissue, after a standard course, long-term maintenance therapy with Longidaza is recommended with breaks between injections - 10-14 days. To increase the bioavailability of drugs and diagnostic agents, a dose of 1500 IU is recommended with a preliminary 10-15 minutes intramuscular or subcutaneous injection into the same place as the main drug. Dilution The contents of the Longidaza ampoule or bottle are dissolved in 1-2 ml of procaine solution (0.25% or 0.5%). In case of intolerance to procaine, the drug is dissolved in the same volume of 0.9% sodium chloride solution for injection or water for injection. When used to increase bioavailability, the contents of the Longidaza ampoule or vial are dissolved in 2 ml, and with a dose of 1500 IU - in 1 ml of 0.9% sodium chloride solution for injection. The solvent must be introduced into the vial or ampoule slowly, wait for 2-3 minutes, and carefully mix without shaking so as not to foam the protein. The prepared solution for parenteral administration cannot be stored. Do not administer IV! Recommended prevention and treatment regimens For the prevention of adhesive disease and severe scarring after surgical interventions on the abdominal and pelvic organs IM at a dose of 3000 IU 1 time every 3 days for a course of 5 injections. If necessary, the use of the drug can be continued with a general course of up to 10 injections when administered once every 5 days. For treatment in gynecology: adhesions in the pelvis for inflammatory diseases of the internal genital organs - intramuscularly once every 3-5 days for a course of 10-15 injections; tubo-peritoneal infertility - IM with a general course of up to 15 injections: the first 5 injections 1 time in 3 days, then - 1 time in 5 days. in urology: chronic prostatitis - intramuscularly once every 5 days, in a course of 10-15 injections; interstitial cystitis - intramuscularly once every 5 days, for a course of up to 10 injections. in surgery: adhesive disease after surgical interventions on the abdominal organs - intramuscularly once every 3-5 days for a course of 10 to 15 injections; long-term non-healing wounds - intramuscularly once every 5 days with a course of 5-10 injections. in dermatovenereology, cosmetology: limited scleroderma - intramuscularly once every 3-5 days for a course of up to 20 injections. The dose and course are selected individually depending on the clinical course, stage, location of the disease and the individual characteristics of the patient; keloid, hypertrophic and developing scars after pyoderma, burns, operations, injuries - intra-scar or subcutaneous injection near the site of the lesion, administration 1 time every 3 days, for a course of up to 15 injections at a dosage of 3000-4500 IU. The volume of dilution of the drug Longidaza is selected by the doctor depending on the number of points of administration. If necessary, the course can be continued according to the scheme once every 5 days up to 25 injections. Depending on the area of skin damage and the age of scar formation, alternating subcutaneous and intramuscular administration is possible once every 5 days at a dose of 3000 IU, for a course of up to 20 injections. in pulmonology and phthisiology: pneumosclerosis - intramuscularly once every 5 days for a course of 10 injections; fibrosing alveolitis - intramuscularly once every 5 days for a course of 15 injections, then maintenance therapy once every 10 days for a total course of up to 25 injections; tuberculosis - intramuscularly once every 5 days for a course of up to 25 injections; Depending on the clinical picture and severity of the disease, long-term therapy is possible (from 6 months to 1 year at a dose of 3000 IU once every 10 days). in orthopedics: joint contractures - subcutaneously near the site of the lesion at a dose of 3000 IU once every 3 days for a course of 5 to 15 injections; arthrosis, ankylosing spondylitis - subcutaneous injection near the site of the lesion in a dose of 3000 IU once every 3 days for a course of up to 15 injections, if necessary, treatment can be continued with injections once every 5 days. The duration of maintenance therapy is selected by the doctor depending on the severity of the disease; hematomas - subcutaneously near the site of the lesion at a dose of 3000 IU once every 3 days for a course of up to 5 injections. To increase bioavailability: when administered subcutaneously or intramuscularly with diagnostic or medicinal drugs (antibiotics, chemotherapy drugs, anesthetics and others), Longidase is administered 10-15 minutes beforehand at a dose of 1500 IU in the same way and in the same place, as the main drug.

Directions for use and doses

Rectally, 1 sup. 1 time per day after cleansing the intestines.

Vaginally, 1 time per day (at night) 1 sup. inserted into the vagina in a lying position.

Longidaza® suppositories 3000 IU are recommended in a course of 10 to 20 administrations.

The administration regimen is adjusted depending on the severity, stage and duration of the disease: Longidaza® is prescribed every other day or at intervals of 2-3 days.

Recommended regimens and doses:

— in urology: 1 sup. every other day - 10 injections, then after 2-3 days - 10 injections, a total course of 20 supp.;

- in gynecology: rectally or vaginally 1 supp. after 2 days - 10 injections, then, if necessary, maintenance therapy is prescribed;

— in dermatovenerology: 1 supp. after 1-2 days - 10-15 injections;

— in surgery: 1 sup. after 2–3 days - 10 injections;

— in pulmonology and phthisiology: 1 supp. after 2-4 days - 10-20 injections.

If necessary, a repeat course of Longidase® is recommended no earlier than after 3 months or long-term maintenance therapy - 1 supp. Once every 5–7 days for 3–4 months.

Longidaza

Methods of application are selected by the doctor depending on the diagnosis, severity of the disease, clinical course, and age of the patient. If necessary, a repeat course is recommended after 2-3 months.

In the case of treatment of diseases accompanied by a severe chronic productive process in the connective tissue, after a standard course, long-term maintenance therapy with Longidaza is recommended with breaks between injections - 10-14 days.

To increase the bioavailability of drugs and diagnostic agents, a dose of 1500 IU is recommended with a preliminary 10-15 minutes intramuscular or subcutaneous injection into the same place as the main drug.

Breeding

The contents of the ampoule or bottle of Longidaza are dissolved in 1-2 ml of procaine solution (0.25% or 0.5%). In case of intolerance to procaine, the drug is dissolved in the same volume of 0.9% sodium chloride solution for injection or water for injection.

When used to increase bioavailability, the contents of the Longidaza ampoule or vial are dissolved in 2 ml, and with a dose of 1500 IU - in 1 ml of 0.9% sodium chloride solution for injection.

The solvent must be introduced into the vial or ampoule slowly, wait for 2-3 minutes, and carefully mix without shaking so as not to foam the protein. The prepared solution for parenteral administration cannot be stored. Do not administer IV!

Recommended prevention and treatment regimens

For the prevention of adhesive disease and severe scarring after surgical interventions on the abdominal and pelvic organs, IM at a dose of 3000 IU once every 3 days for a course of 5 injections. If necessary, the use of the drug can be continued with a general course of up to 10 injections when administered once every 5 days.

For treatment

in gynecology:

adhesions in the pelvis for inflammatory diseases of the internal genital organs - intramuscularly once every 3-5 days for a course of 10-15 injections;

tubo-peritoneal infertility - IM with a general course of up to 15 injections: the first 5 injections 1 time in 3 days, then - 1 time in 5 days.

in urology:

chronic prostatitis - intramuscularly once every 5 days, with a course of 10-15 injections;

interstitial cystitis - intramuscularly once every 5 days, for a course of up to 10 injections.

in surgery:

adhesive disease after surgical interventions on the abdominal organs - intramuscularly once every 3-5 days for a course of 10 to 15 injections;

long-term non-healing wounds - intramuscularly once every 5 days with a course of 5-10 injections.

in dermatovenerology, cosmetology:

limited scleroderma - intramuscularly once every 3-5 days for a course of up to 20 injections. The dose and course are selected individually depending on the clinical course, stage, location of the disease and the individual characteristics of the patient;

keloid, hypertrophic and developing scars after pyoderma, burns, operations, injuries - intra-scar or subcutaneous injection near the site of the lesion, administration 1 time every 3 days, for a course of up to 15 injections at a dosage of 3000-4500 IU. The volume of dilution of the drug Longidaza is selected by the doctor depending on the number of points of administration. If necessary, the course can be continued according to the scheme once every 5 days up to 25 injections. Depending on the area of skin damage and the age of scar formation, alternating subcutaneous and intramuscular administration is possible once every 5 days at a dose of 3000 IU, for a course of up to 20 injections.

in pulmonology and phthisiology:

pneumosclerosis - intramuscularly once every 5 days for a course of 10 injections;

fibrosing alveolitis - intramuscularly once every 5 days for a course of 15 injections, then maintenance therapy once every 10 days for a total course of up to 25 injections;

tuberculosis - intramuscularly once every 5 days for a course of up to 25 injections; Depending on the clinical picture and severity of the disease, long-term therapy is possible (from 6 months to 1 year at a dose of 3000 IU once every 10 days).

in orthopedics:

joint contractures - subcutaneously near the site of the lesion at a dose of 3000 IU once every 3 days for a course of 5 to 15 injections;

arthrosis, ankylosing spondylitis - subcutaneous injection near the site of the lesion in a dose of 3000 IU once every 3 days for a course of up to 15 injections, if necessary, treatment can be continued with injections once every 5 days. The duration of maintenance therapy is selected by the doctor depending on the severity of the disease;

hematomas - subcutaneously near the site of the lesion at a dose of 3000 IU once every 3 days for a course of up to 5 injections.

To increase bioavailability: when administered subcutaneously or intramuscularly with diagnostic or medicinal drugs (antibiotics, chemotherapy drugs, anesthetics and others), Longidase is administered 10-15 minutes beforehand at a dose of 1500 IU in the same way and in the same place, as the main drug.